Mesenchymal Stem Cell Therapy for CRP-Linked Inflammatory Lung Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet therapeutic need for new treatment options for inflammatory lung diseases such as COPD, PAH, asthma, and ARDS, particularly in patients with elevated circulating C-reactive protein levels, as the underlying causes of these conditions remain poorly understood.
Innovation Solution
Administering a composition of culture-expanded, cryopreserved mesenchymal lineage precursor or stem cells (MLPSCs) to patients with elevated CRP levels, specifically through intravenous routes, to treat or prevent inflammatory lung diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If allogeneic mesenchymal stem cells are used for treatment, then cell availability is improved, but risk of viral transmission and immune rejection increases
Solution Approach 1:
The patent uses an intermediary approach by culturing cells in defined serum-free media with specific growth factors and supplements that act as mediators to support cell growth without introducing animal-derived contaminants, thereby enabling allogeneic cell availability while minimizing viral transmission risks
Solution Approach 2:
The patent changes the cultural parameters from traditional serum-containing media to defined serum-free media with controlled composition including specific growth factors, cytokines, and supplements, transforming the cell culture system to achieve both cell availability and safety
2Object-affected harmful factors
If defined serum-free media is used for cell culture, then viral transmission risk is reduced, but manufacturing complexity increases
Solution Approach 1:
The patent segments the cell culture process into distinct phases with optimized media formulations for each stage (expansion, differentiation, formulation), allowing complex manufacturing requirements to be managed through modular, standardized protocols
Solution Approach 2:
The patent develops universal defined serum-free media formulations that can support multiple cell types and culture conditions, reducing manufacturing complexity by eliminating the need for cell-type-specific serum formulations while maintaining safety
3Reliability
If mesenchymal stem cells are differentiated into lung lineage cells, then therapeutic efficacy for lung diseases is improved, but differentiation control difficulty increases
Solution Approach 1:
The patent applies preliminary action by pre-differentiating mesenchymal stem cells into lung lineage cells under controlled conditions before transplantation, ensuring cells are primed with appropriate lung-specific characteristics and markers that enhance therapeutic efficacy while simplifying post-transplantation outcomes
Solution Approach 2:
The patent implements feedback control mechanisms by monitoring cell differentiation markers and morphology throughout the differentiation process, adjusting culture conditions in response to measured parameters to maintain optimal differentiation control and ensure therapeutic quality
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to method of treating or preventing an inflammatory lung disease in a subject in need thereof, the method comprising administering to the subject a composition comprising mesenchymal lineage precursor or stem cells (MLPSCs).